Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment NORWOOD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. CRBP ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the U.S.…
#norwood #mass #corbus #fda #αvβ8 #sitc #yuvalcohenphd #cb1 #massachusetts #linkedin